Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003071101 | SCV003450776 | likely benign | Acroosteolysis-keloid-like lesions-premature aging syndrome; Basal ganglia calcification, idiopathic, 4; Infantile myofibromatosis; Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome | 2022-11-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004070350 | SCV005002073 | uncertain significance | Inborn genetic diseases | 2023-09-22 | criteria provided, single submitter | clinical testing | The c.542G>C (p.G181A) alteration is located in exon 4 (coding exon 3) of the PDGFRB gene. This alteration results from a G to C substitution at nucleotide position 542, causing the glycine (G) at amino acid position 181 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003898732 | SCV004708244 | uncertain significance | PDGFRB-related disorder | 2024-03-01 | no assertion criteria provided | clinical testing | The PDGFRB c.542G>C variant is predicted to result in the amino acid substitution p.Gly181Ala. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0026% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |